GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Cyclically Adjusted Price-to-FCF

Biomerica (Biomerica) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomerica Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biomerica's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Cyclically Adjusted Price-to-FCF Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomerica's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Biomerica's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biomerica's Cyclically Adjusted Price-to-FCF falls into.



Biomerica Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biomerica's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, Biomerica's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.108/129.4194*129.4194
=-0.108

Current CPI (Feb. 2024) = 129.4194.

Biomerica Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201405 -0.023 100.373 -0.030
201408 0.019 100.352 0.025
201411 0.003 99.635 0.004
201502 -0.067 99.032 -0.088
201505 -0.012 100.333 -0.015
201508 -0.027 100.548 -0.035
201511 -0.033 100.135 -0.043
201602 0.025 100.040 0.032
201605 -0.005 101.355 -0.006
201608 -0.009 101.617 -0.011
201611 -0.029 101.829 -0.037
201702 -0.010 102.779 -0.013
201705 -0.039 103.256 -0.049
201708 -0.017 103.587 -0.021
201711 -0.032 104.072 -0.040
201802 -0.060 105.052 -0.074
201805 -0.043 106.148 -0.052
201808 -0.092 106.383 -0.112
201811 -0.030 106.338 -0.037
201902 -0.031 106.649 -0.038
201905 -0.109 108.048 -0.131
201908 -0.002 108.245 -0.002
201911 -0.037 108.519 -0.044
202002 -0.048 109.139 -0.057
202005 -0.323 108.175 -0.386
202008 -0.144 109.662 -0.170
202011 -0.112 109.793 -0.132
202102 -0.123 110.968 -0.143
202105 -0.088 113.576 -0.100
202108 0.000 115.421 0.000
202111 0.103 117.269 0.114
202202 0.182 119.703 0.197
202205 -0.333 123.323 -0.349
202208 -0.123 124.958 -0.127
202211 -0.092 125.607 -0.095
202302 -0.128 126.928 -0.131
202305 -0.059 128.314 -0.060
202308 -0.103 129.538 -0.103
202311 -0.051 129.548 -0.051
202402 -0.108 129.419 -0.108

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomerica  (NAS:BMRA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biomerica Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biomerica's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663